Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
187.21
+0.15 (+0.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
59
60
Next >
(BIIB) - Analyzing Biogen's Short Interest
↗
March 17, 2023
Via
Benzinga
Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year
↗
March 16, 2023
Via
Benzinga
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
↗
March 16, 2023
Via
Benzinga
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
March 16, 2023
From
Biogen Inc.
Via
GlobeNewswire
Biogen's Debt Overview
↗
March 15, 2023
Via
Benzinga
1 Reason to Buy Biogen Stock, and 1 Reason to Sell
↗
March 14, 2023
It could be a make or break year for the biotech.
Via
The Motley Fool
Reata Pharma Stock Halted After Winning 'Coin-Flip' FDA Approval
↗
February 28, 2023
The FDA approved Reata's Friedreich's ataxia treatment, Skyclarys.
Via
Investor's Business Daily
Biogen (BIIB) Q4 2022 Earnings Call Transcript
↗
February 15, 2023
BIIB earnings call for the period ending December 31, 2022.
Via
The Motley Fool
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode
March 15, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for...
Via
FinancialNewsMedia
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
↗
March 14, 2023
Via
Benzinga
Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
March 14, 2023
Avid Bioservices Inc. (NASDAQ: CDMO) is a contract development and manufacturing organization (CDMO) that specializes in producing monoclonal antibodies,
Via
MarketBeat
Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone
↗
March 13, 2023
Via
Benzinga
Why Biogen Stock Is Falling Today
↗
February 15, 2023
Via
Benzinga
Biogen Inches Higher On Quarterly Beat, Guides To 'Modest' Alzheimer's Drug Sales
↗
February 15, 2023
The company expects "modest" Leqembi sales, but there's a caveat.
Via
Investor's Business Daily
Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed
↗
March 09, 2023
The company is definitively closing the door on solanezumab.
Via
Investor's Business Daily
Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock
↗
March 09, 2023
Any Alzheimer's drug that worked would be an instant blockbuster, but science doesn't work on an investor's schedule.
Via
InvestorPlace
Elliott Wave Technical Analysis: Biogen Inc. - Wednesday, March 8
↗
March 08, 2023
Looking for a bottom in wave {v} to then look for longs.
Via
Talk Markets
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
March 08, 2023
From
Biogen Inc.
Via
GlobeNewswire
Why Shares of Anavex Life Sciences Rose 12.4% in February
↗
March 06, 2023
The company's first-quarter earnings report detailed positive news regarding its pipeline.
Via
The Motley Fool
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
↗
March 06, 2023
Via
Benzinga
FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
March 05, 2023
From
Biogen Inc.
Via
GlobeNewswire
What Does Biogen's Debt Look Like?
↗
March 02, 2023
Shares of Biogen Inc. (NASDAQ:BIIB) moved lower by 7.52% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its...
Via
Benzinga
Peering Into Biogen's Recent Short Interest
↗
March 01, 2023
Biogen's (NASDAQ:BIIB) short percent of float has fallen 8.84% since its last report. The company recently reported that it has 1.71 million shares sold short, which is 1.34% of all regular shares that...
Via
Benzinga
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
February 27, 2023
From
Biogen Inc.
Via
GlobeNewswire
Reata Stock Plummets As Official's Exit Shakes Up FDA's Neuroscience Unit
↗
February 27, 2023
The FDA is set to review the company's neurological drug by Tuesday.
Via
Investor's Business Daily
Why Reata Pharmaceuticals Shares Are Falling Monday?
↗
February 27, 2023
According to various reports, the FDA's neuroscience expert Billy Dunn is leaving the agency after more than 15 years, effective immediately.
Via
Benzinga
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
↗
February 25, 2023
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between...
Via
Talk Markets
3 More Mid-Cap Biotechs The Street Sees Doubling
February 22, 2023
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk.
Via
MarketBeat
Analyst Initiates Coverage of GE Healthcare, Says' Path To Greatness Well-Paved'
↗
February 17, 2023
Via
Benzinga
Biogen Beats Q4 Earnings & Sales Estimates, Stock Up
↗
February 15, 2023
Biogen reported fourth-quarter 2022 adjusted earnings per share (EPS) of $4.05.
Via
Talk Markets
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
59
60
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
